surmount-1 tirzepatide weight loss nondiabetic after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial Non-Diabetic Weight Loss with Tirzepatide

A peptide may be sufficiently stable for controlled laboratory handling while still lacking validated human safety data

Last fall, 12% of U.S

Currently, none of these medications are FDA-approved for prediabetes

But there is a key exception when an FDA-approved drug is on the official shortage list

Conclusions and Relevance: The current evidence underscores the potential of GLP-1 RAs as a novel therapeutic approach for certain psychiatric disorders, particularly alcohol-related disorders, depression, and autism-related food behaviors

The peptide space has attracted plenty of hype and plenty of low-quality products